XOMA ROYALTY CORP - XOMA 8 3/8 PERP(NASDAQ:XOMAO) stock Fundamental Analysis

Fundamental Rating

Overall XOMAO gets a fundamental rating of 3 out of 10. We evaluated XOMAO against 567 industry peers in the Biotechnology industry. XOMAO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, XOMAO is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year XOMAO has reported negative net income.

In the past year XOMAO has reported a negative cash flow from operations.

In multiple years XOMAO reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: XOMAO reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of XOMAO (-11.87%) is better than 85.54% of its industry peers.

XOMAO's Return On Equity of -32.06% is fine compared to the rest of the industry. XOMAO outperforms 76.37% of its industry peers.

		Industry Rank	Sector Rank
ROA	-11.87%
ROE	-32.06%
ROIC	N/A

ROA(3y)-14.85%

ROA(5y)-6.52%

ROE(3y)-31.32%

ROE(5y)-15.58%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

XOMAO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

XOMAO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for XOMAO has been increased compared to 1 year ago.

Compared to 5 years ago, XOMAO has more shares outstanding

The debt/assets ratio for XOMAO is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -6.03, we must say that XOMAO is in the distress zone and has some risk of bankruptcy.

XOMAO has a worse Altman-Z score (-6.03) than 63.84% of its industry peers.

A Debt/Equity ratio of 1.30 is on the high side and indicates that XOMAO has dependencies on debt financing.

The Debt to Equity ratio of XOMAO (1.30) is worse than 79.89% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.3
Debt/FCF	N/A
Altman-Z	-6.03

ROIC/WACCN/A

WACC10.48%

2.3 Liquidity

A Current Ratio of 5.15 indicates that XOMAO has no problem at all paying its short term obligations.

XOMAO has a Current ratio (5.15) which is comparable to the rest of the industry.

A Quick Ratio of 5.15 indicates that XOMAO has no problem at all paying its short term obligations.

XOMAO has a Quick ratio (5.15) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.15
Quick Ratio	5.15

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.63% over the past year.

Looking at the last year, XOMAO shows a very strong growth in Revenue. The Revenue has grown by 529.37%.

The Revenue has been growing by 9.17% on average over the past years. This is quite good.

EPS 1Y (TTM)4.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.16%

Revenue 1Y (TTM)529.37%

Revenue growth 3Y-9.28%

Revenue growth 5Y9.17%

Sales Q2Q%375.4%

3.2 Future

The Earnings Per Share is expected to grow by 40.76% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 34.78% on average over the next years. This is a very strong growth

EPS Next Y72.39%

EPS Next 2Y46.55%

EPS Next 3Y40.76%

EPS Next 5YN/A

Revenue Next Year15.45%

Revenue Next 2Y24.65%

Revenue Next 3Y34.78%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

XOMAO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year XOMAO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XOMAO's earnings are expected to grow with 40.76% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y46.55%

EPS Next 3Y40.76%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

XOMAO has a Yearly Dividend Yield of 8.28%, which is a nice return.

Compared to an average industry Dividend Yield of 5.94, XOMAO pays a better dividend. On top of this XOMAO pays more dividend than 99.29% of the companies listed in the same industry.

Compared to an average S&P500 Dividend Yield of 2.47, XOMAO pays a better dividend.

		Industry Rank	Sector Rank
Dividend Yield	8.28%

5.2 History

XOMAO has been paying a dividend for over 5 years, so it has already some track record.

XOMAO has not decreased its dividend in the last 3 years.

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years3

5.3 Sustainability

XOMAO has negative earnings and hence a negative payout ratio. The dividend may be in danger.

DP-20.83%

EPS Next 2Y46.55%

EPS Next 3Y40.76%

More info and screens

Find the best dividend stocks

Show peers with best dividend

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

NASDAQ:XOMAO (4/25/2025, 8:00:01 PM)

25.28

+0.03 (+0.12%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-17 2025-03-17/amc

Earnings (Next)05-13 2025-05-13

Inst Owners61.19%

Inst Owner ChangeN/A

Ins Owners0.87%

Ins Owner ChangeN/A

Market Cap302.10M

Analysts82.22

Price Target71.92 (184.49%)

Short Float %0.03%

Short Ratio1.05

Dividend

		Industry Rank	Sector Rank
Dividend Yield	8.28%

Yearly Dividend0.47

Dividend Growth(5Y)N/A

DP-20.83%

Div Incr Years0

Div Non Decr Years3

Ex-Date04-03 2025-04-03 (0.52344)

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-151.21%

Min EPS beat(2)-256.98%

Max EPS beat(2)-45.44%

EPS beat(4)1

Avg EPS beat(4)25.29%

Min EPS beat(4)-256.98%

Max EPS beat(4)407.67%

EPS beat(8)2

Avg EPS beat(8)4.72%

EPS beat(12)3

Avg EPS beat(12)-25.23%

EPS beat(16)4

Avg EPS beat(16)-50.15%

Revenue beat(2)1

Avg Revenue beat(2)3.15%

Min Revenue beat(2)-2.38%

Max Revenue beat(2)8.67%

Revenue beat(4)3

Avg Revenue beat(4)11.55%

Min Revenue beat(4)-2.38%

Max Revenue beat(4)29.78%

Revenue beat(8)4

Avg Revenue beat(8)1.67%

Revenue beat(12)5

Avg Revenue beat(12)-10.02%

Revenue beat(16)6

Avg Revenue beat(16)-20.19%

PT rev (1m)-20.54%

PT rev (3m)-16.44%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-137.04%

EPS NY rev (1m)0%

EPS NY rev (3m)-1.03%

Revenue NQ rev (1m)4.62%

Revenue NQ rev (3m)-9.43%

Revenue NY rev (1m)-9.03%

Revenue NY rev (3m)-9.03%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	10.08
P/FCF	N/A
P/OCF	N/A
P/B	3.69
P/tB	5.39
EV/EBITDA	N/A

EPS(TTM)-2.06

EYN/A

EPS(NY)-0.57

Fwd EYN/A

FCF(TTM)-2.84

FCFYN/A

OCF(TTM)-1.15

OCFYN/A

SpS2.51

BVpS6.86

TBVpS4.69

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-11.87%
ROE	-32.06%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-14.85%

ROA(5y)-6.52%

ROE(3y)-31.32%

ROE(5y)-15.58%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.14

Health

		Industry Rank	Sector Rank
Debt/Equity	1.3
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	9350%
Cap/Sales	67.37%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.15
Quick Ratio	5.15
Altman-Z	-6.03

F-Score5

WACC10.48%

ROIC/WACCN/A

Cap/Depr(3y)7738.51%

Cap/Depr(5y)4653.1%

Cap/Sales(3y)108.05%

Cap/Sales(5y)64.84%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)4.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.16%

EPS Next Y72.39%

EPS Next 2Y46.55%

EPS Next 3Y40.76%

EPS Next 5YN/A

Revenue 1Y (TTM)529.37%

Revenue growth 3Y-9.28%

Revenue growth 5Y9.17%

Sales Q2Q%375.4%

Revenue Next Year15.45%

Revenue Next 2Y24.65%

Revenue Next 3Y34.78%

Revenue Next 5YN/A

EBIT growth 1Y52.05%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year109.94%

EBIT Next 3Y53.42%

EBIT Next 5YN/A

FCF growth 1Y-86.76%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y24.29%

OCF growth 3YN/A

OCF growth 5YN/A

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens